24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Startup: Confidential
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Drug
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
09:12
“Israeli startups have established a reputation for best-in-class innovation”
09:11
AI will cause trust issues during the 2024 election campaign, says Team8
09:11
“We really see the GenAI industry and the ecosystem changing in front of our eyes”
09:11
“I don't think AI will take everyone's job. I think it will change jobs.”
More stories
Buzz
Most popular
Daily
Weekly
1
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
2
Wiz shareholders finalizing secondary deals worth hundreds of millions of dollars
3
Bill Ackman: "Israel needs support more than ever and I can help"
4
Cyber decacorn Wiz in advanced negotiation to acquire Lacework for $150-200 million
5
Guardians of innovation: The rise of Israel’s civilian defense-tech
More news
Drug
15 stories about Drug
Teva is recruiting Israeli academia to help produce its next breakthrough drug
13.09.20
|
CTech
You reap what you sow: The pharmaceutical giant is partnering up with researchers to try and find the next Copaxone
A quantum leap In the drug development world
23.08.20
|
CTech
Microfluidic chips that simulate human tissue enable us to conduct medical experiments in ways that could not have been even imagined only a few years ago. Two leading Israeli researchers report from the turbulent Israeli front line of the global 'organ-on-a-chip' sector
Life Sciences Venture Fund aMoon Invests $5 Million in Cancer Drug Company
24.12.19
|
Hagar Ravet
NanoGhosts turns stem cells into a drug delivery system that specifically targets cancerous tumors
Cannabis Producer Cannbit Snags THC Research Pioneer Raphael Mechoulam
04.03.19
|
Adi Pick
Mechoulam is a professor at the Institute for Drug Research at the Hebrew University of Jerusalem and is the subject of a 2015 movie documentary called The Scientist
Teva Agrees to Stop Selling Amgen Generic Following Patent Infringement Settlement
03.01.19
|
Lilach Baumer
In December, Teva reached a confidential settlement and licensing agreement with drug manufacturer Neos Therapeutics, regarding its generic version for Neos' ADHD drug
Teva, Mylan Drop on Announcement of Epinephrine Injector Rival
09.12.18
|
Lilach Baumer
Novartis’ U.S. division Sandoz announced a planned release for early 2019. The company will sell its drug, which lacks the EpiPen’s auto-injector, for $250 a pair out of pocket, compared to Mylan and Teva’s $300
Gastro Treatment Company RedHill Announces Successful Clinical Trial in Treatment of H. Pylori Infection
04.12.18
|
CTech
RedHill’s new pill managed to eradicate 84% of H. pylori bacteria, as opposed to 58% in patients receiving the standard of care
Teva, Celltrion Gain FDA Approval for Generic Blood Cancer Bio-Drug
29.11.18
|
Lilach Baumer
Called Truxima, the drug has been approved to treat several conditions of non-Hodgkin’s lymphoma
Dutch Animal Feed Company Nutreco Invests in Medical Aquafarming Startup ViAqua
05.07.18
|
CTech
ViAqua develops a particle-based matrix for delivering antiviral medication to shrimp
MediWound’s Pineapple-Based Burn Treatment to Treat Mustard Gas Burns
31.05.18
|
Dror Reich
The Nasdaq-listed, Israeli based company received the FDA’s approval to expand the use of flagship burn treatment NexoBrid to those suffering from Sulfur Mustard injuries
Israeli Cannabis Device Developer Kanabo to Set Up Marijuana Farm in Europe
27.04.18
|
Tofi Stoler
To carry out the plan, Kanabo is partnering with San Francisco-Based Cannabis Extract Manufacturer Constance Therapeutics
An Israeli Company Wants to Treat Tourette Syndrome With Cannabis
09.04.18
|
Lilach Baumer
Therapix Biosciences announced the successful completion of phase 2 clinical trial of its cannabinoid-based drug, conducted at Yale University Monday
Teva Wants to Be Like Mylan: Agile, Lean and Profitable
17.12.17
|
Uri Tal-Tenne
The cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
Former Teva Executive One Step Closer to Bringing Copaxone Rival to Market
31.10.17
|
Lilach Baumer
Mapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot
Teva Submits Potential Moneymaker Migraine Drug for FDA Approval
18.10.17
|
Dror Reich and Lilach Baumer
Teva’s patent for its moneymaker multiple sclerosis drug Copaxone expired last year
Please ensure Javascript is enabled for purposes of
website accessibility